Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares IssuedShort-Term Debt repayments
Ratios

BeOne Medicines (BEIGF) Short-Term Debt repayments (2020 - 2025)

BeOne Medicines (BEIGF) has disclosed Short-Term Debt repayments for 6 consecutive years, with $769.0 million as the latest value for Q4 2025.

  • Quarterly Short-Term Debt repayments rose 40.66% to $769.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, up 48.36% year-over-year, with the annual reading at $1.0 billion for FY2025, 48.36% up from the prior year.
  • Short-Term Debt repayments for Q4 2025 was $769.0 million at BeOne Medicines, up from $102.9 million in the prior quarter.
  • The five-year high for Short-Term Debt repayments was $769.0 million in Q4 2025, with the low at $16.0 million in Q2 2021.
  • Average Short-Term Debt repayments over 5 years is $170.1 million, with a median of $97.9 million recorded in 2023.
  • The sharpest move saw Short-Term Debt repayments soared 1575.76% in 2021, then tumbled 60.78% in 2023.
  • Over 5 years, Short-Term Debt repayments stood at $205.2 million in 2021, then skyrocketed by 32.37% to $271.7 million in 2022, then tumbled by 44.78% to $150.0 million in 2023, then skyrocketed by 264.48% to $546.7 million in 2024, then surged by 40.66% to $769.0 million in 2025.
  • According to Business Quant data, Short-Term Debt repayments over the past three periods came in at $769.0 million, $102.9 million, and $172.9 million for Q4 2025, Q2 2025, and Q1 2025 respectively.